{"id":42390,"date":"2026-04-30T13:51:30","date_gmt":"2026-04-30T08:21:30","guid":{"rendered":"https:\/\/prolifics.com\/usa\/?p=42390"},"modified":"2026-04-30T14:08:03","modified_gmt":"2026-04-30T08:38:03","slug":"agentic-ai-for-pharma-industry","status":"publish","type":"post","link":"https:\/\/prolifics.com\/usa\/resource-center\/blog\/agentic-ai-for-pharma-industry","title":{"rendered":"Agentic AI for Pharma: The Future of How Work Gets Done"},"content":{"rendered":"\n<p>Agentic AI for pharma is at a turning point. As pressure builds to bring therapies to market, manage rising costs, and navigate increasing complexity, traditional ways of working are no longer enough. Agentic AI is emerging as a powerful shift, enabling smarter, more autonomous ways to move from discovery to patient impact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Pharma Cannot Afford to Stand Still<\/h2>\n\n\n\n<p>A life-saving drug can take years to reach patients because teams are still manually reviewing and reconciling vast amounts of trial data. Meanwhile, organizations using AI are accelerating timelines and making faster, more informed decisions. Today, the real competition is not just about the drug; it is about how efficiently you operate.<\/p>\n\n\n\n<p>The industry now faces growing demand and increasing expectations for innovation. At Prolifics, we help organizations use AI and automation to streamline processes, enhance decision-making, and bring life-saving therapies to patients sooner.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"562\" data-src=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines-1024x562.jpg\" alt=\"Agentic AI for pharma driving measurable impact with 35B market growth 41.5 percent CAGR 40 percent cost reduction and faster regulatory review timelines\" class=\"wp-image-42394 lazyload\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/562;aspect-ratio:1.8220869130035866;width:579px;height:auto\" title=\"\" data-srcset=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines-1024x562.jpg 1024w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines-300x165.jpg 300w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines-768x421.jpg 768w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines-1536x843.jpg 1536w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-driving-measurable-impact-with-35B-market-growth-41.5-percent-CAGR-40-percent-cost-reduction-and-faster-regulatory-review-timelines.jpg 1693w\" data-sizes=\"auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" data-original-sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Pharmaceutical Companies Are Turning to Agentic AI Capabilities<\/h2>\n\n\n\n<p><a href=\"https:\/\/prolifics.com\/usa\/resource-center\/blog\/agentic-ai-in-healthcare\" data-type=\"link\" data-id=\"https:\/\/prolifics.com\/usa\/resource-center\/blog\/agentic-ai-in-healthcare\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Pharmaceutical companies are adopting agentic AI<\/mark><\/a> to handle complex, time-sensitive processes that traditional systems cannot manage efficiently. These AI systems can make decisions, take actions, and adapt in real time across functions like R&amp;D, regulatory, and supply chain.<\/p>\n\n\n\n<p>This shift helps reduce delays, improve accuracy, and accelerate the delivery of therapies while enabling teams to focus on higher-value work.<\/p>\n\n\n\n<p><strong>The following capabilities define what makes agentic AI uniquely suited to the pharmaceutical sector:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Autonomous multi-step reasoning across complex, interconnected pharmaceutical data ecosystems.<\/li>\n\n\n\n<li>Real-time document comprehension spanning clinical trial reports, regulatory submissions, and scientific literature.<\/li>\n\n\n\n<li>Adaptive workflow orchestration that self-corrects based on live feedback and interim results.<\/li>\n\n\n\n<li>Proactive goal decomposition breaking large objectives into executable subtasks without manual input.<\/li>\n\n\n\n<li>Cross-system integration with EHR platforms, CTMS, LIMS, and regulatory databases simultaneously.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"683\" data-src=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Projected-Growth-of-Agentic-AI-North-America-and-Europe-1024x683.jpg\" alt=\"Projected growth of Agentic AI for pharma market in North America and Europe showing rapid adoption and increasing investment in AI in pharmaceutical industry\" class=\"wp-image-42397 lazyload\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/683;aspect-ratio:1.4992793575987737;width:631px;height:auto\" title=\"\" data-srcset=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Projected-Growth-of-Agentic-AI-North-America-and-Europe-1024x683.jpg 1024w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Projected-Growth-of-Agentic-AI-North-America-and-Europe-300x200.jpg 300w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Projected-Growth-of-Agentic-AI-North-America-and-Europe-768x512.jpg 768w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Projected-Growth-of-Agentic-AI-North-America-and-Europe.jpg 1536w\" data-sizes=\"auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" data-original-sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">From Automation to Autonomy: The Shift Pharma Is Facing<\/h2>\n\n\n\n<p>Traditional automation in pharma has relied on rigid, rules-based systems, if X happens, execute Y. While tools like RPA and electronic data capture have improved efficiency, they are inherently brittle, requiring reprogramming when conditions change and lacking the ability to handle new or unexpected scenarios.<\/p>\n\n\n\n<p>Autonomy represents a fundamental shift. Instead of following scripts, autonomous agents understand objectives, assess real-time conditions, choose the right tools, execute actions, and adapt based on outcomes. This is essential in pharma, where trial protocols shift; regulations evolve, and supply chains face constant disruption.<\/p>\n\n\n\n<p>The urgency is clear. MNC projects <a href=\"https:\/\/prolifics.com\/usa\/resource-center\/blog\/predictive-analytics-in-healthcare\" data-type=\"link\" data-id=\"https:\/\/prolifics.com\/usa\/resource-center\/blog\/predictive-analytics-in-healthcare\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">GenAI in healthcare<\/mark><\/a> to grow from $1 billion today to $22 billion by 2027, at an 85% CAGR. Organizations that delay this transition risk losing not just technological ground, but lasting advantages in cost, speed, and innovation.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"683\" data-src=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/AI-Maturity-Spectrum-in-Pharma-1024x683.jpg\" alt=\"From Automation to Autonomy: The Shift Pharma Is Facing\" class=\"wp-image-42400 lazyload\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/683;aspect-ratio:1.4992793575987737;width:586px;height:auto\" title=\"\" data-srcset=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/AI-Maturity-Spectrum-in-Pharma-1024x683.jpg 1024w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/AI-Maturity-Spectrum-in-Pharma-300x200.jpg 300w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/AI-Maturity-Spectrum-in-Pharma-768x512.jpg 768w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/AI-Maturity-Spectrum-in-Pharma.jpg 1536w\" data-sizes=\"auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" data-original-sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Where Pharma Feels the Pain Today<\/h2>\n\n\n\n<p>Despite significant technology investment, pharmaceutical organizations continue to experience acute operational pain across four core domains. These pain points are not isolated inefficiencies; they compound one another, creating systemic drag that delays therapies, inflates costs, and increases compliance risk. Addressing them is central to any credible population health management strategy for 2026 and beyond.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">R&amp;D and Clinical Trials<\/h3>\n\n\n\n<p>Drug development remains one of the most expensive and time-intensive processes in any industry, with average development costs exceeding $2.6 billion per approved molecule and timelines stretching to fifteen years. Clinical trial operations are particularly burdened by manual data reconciliation, slow patient recruitment, and high screen-failure rates that consume resources without advancing scientific goals.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Machine learning screening<\/strong> has been shown to reduce screen-failure rates from 45% to 18%, saving up to $8 million per program (<strong>JAMA Oncology, 2025<\/strong>).\u00a0<\/li>\n\n\n\n<li>Manual medical writing for clinical study reports can consume 2,000 to 4,000 hours per submission cycle per compound.\u00a0<\/li>\n\n\n\n<li>Adaptive trial algorithms already cut enrollment timelines by approximately 40%, according to pharmacovigilance research published in 2025.\u00a0<\/li>\n\n\n\n<li>Data silos between CTMS, EDC, and biostatistics platforms create reconciliation bottlenecks that delay interim analysis by weeks.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Regulatory and Compliance<\/h3>\n\n\n\n<p>Regulatory submission has become one of the highest-friction processes in the pharmaceutical value chain. Submissions to the FDA or EMA can involve tens of thousands of pages of structured and unstructured documentation, and even minor inconsistencies can trigger complete response letters that set timelines back by twelve months or more.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The<strong> FDA&#8217;s May 2025 NLP pilot<\/strong> analyzed 12,000 pages of study reports in hours, a task previously requiring weeks of human review.<\/li>\n\n\n\n<li>The <strong>UK&#8217;s MHRA AI Airlock Sandbox<\/strong> reduced approval cycles by seven months for sponsors using explainable AI algorithms in submissions.<\/li>\n\n\n\n<li>Over <strong>51% of pharma professionals<\/strong> cite resistance to change as the primary barrier to agentic AI adoption in regulatory workflows (<strong>Pistoia Alliance, 2025<\/strong>).<\/li>\n\n\n\n<li>Post-market pharmacovigilance engines mining electronic health records in near real-time are now demonstrating a 40% improvement in safety signal detection over rule-based systems.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Supply Chain and Manufacturing<\/h3>\n\n\n\n<p>Pharmaceutical supply chains are among the most complex in the world, spanning raw material sourcing, cold chain logistics, batch manufacturing, and serialization compliance across dozens of jurisdictions. The COVID-19 pandemic exposed the fragility of these networks, and recovery has been slower than anticipated because the underlying data infrastructure remains fragmented.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AI-driven inspection systems are now capable of distinguishing acceptable from defective pharmaceutical components at speeds far exceeding manual inspection, reducing yield loss and throughput delays.<\/li>\n\n\n\n<li>Demand forecasting errors in pharma supply chains regularly result in either costly overproduction or dangerous stockouts affecting patient access in emerging markets.<\/li>\n\n\n\n<li>42% of pharma firms now use cloud-based platforms, achieving 52% faster trial-related data integration and improved end-to-end supply visibility.<\/li>\n\n\n\n<li>Scaling health interventions in emerging markets requires supply chain AI that can model local demand patterns, regulatory variability, and cold chain constraints simultaneously.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Commercial and Patient Engagement<\/h3>\n\n\n\n<p>The commercial model in pharmaceuticals is undergoing significant disruption. Market access blocks now affect nearly two-thirds of US covered lives within the first six to twelve months of a product launch, precisely the window when commercial investment is at its peak. Meanwhile, HCP engagement models built on static CRM journeys are increasingly misaligned with the dynamic, digital-first behaviors of modern prescribers.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>New-to-market access blocks affected 56% of US covered lives in 2024, growing to nearly two-thirds by 2025, according to MMIT research.<\/li>\n\n\n\n<li>Less than 10% of new pharmaceutical launches achieve international excellence across two or more countries.<\/li>\n\n\n\n<li>Personalized, AI-generated HCP materials can drive revenue increases of up to 10% while reducing external agency costs by 25%.<\/li>\n\n\n\n<li>Agentic commercial systems are compressing the time from payer policy change to commercial response from months to days for organizations with unified intelligence infrastructure.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How Agentic AI Changes the Game<\/h2>\n\n\n\n<p>Agentic AI is not just accelerating tasks in pharma; it is reshaping the economics of knowledge to work. By autonomously interpreting complex clinical, regulatory, and scientific data, these systems significantly reduce time, cost, and human effort across high-value processes. Early adoption data already shows measurable gains in cost efficiency, speed, and operational agility, with impacts expected to compound as systems mature. More importantly, agentic orchestration connects workflows across functions, enabling a level of cross-domain intelligence that traditional automation cannot achieve.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>End-to-end medical writing automation compresses documentation timelines from months to days, freeing scientific teams for higher-value research.<\/li>\n\n\n\n<li>Agentic regulatory intelligence continuously monitors evolving guidance and flags impacted submissions in real time.<\/li>\n\n\n\n<li>AI-driven clinical data review identifies protocol deviations and adverse events proactively, not retrospectively.<\/li>\n\n\n\n<li>Cross-functional coordination improves as agentic layers surface bottlenecks and translate complex data into compliant, actionable insights.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Real-World Pharma Applications of Agentic AI | A Prolifics View<\/h2>\n\n\n\n<p>Agentic AI is already delivering measurable results across the pharmaceutical value chain, and at <strong>Prolifics<\/strong>, we are helping organizations translate these innovations into scalable, enterprise-ready solutions.<\/p>\n\n\n\n<p><strong>Here are some of the most impactful real-world use cases shaping the industry today:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Medical Writing<\/strong><br>\u00a0AI-driven agents are streamlining clinical documentation, reducing clinical study report timelines while improving accuracy and consistency. This allows teams to focus more on scientific insight rather than manual effort; a shift of Prolifics actively supports intelligent automation frameworks.<\/li>\n\n\n\n<li><strong>Faster Regulatory Reviews<\/strong><br>\u00a0Regulatory bodies are leveraging agentic AI to improve efficiency, with early deployments showing significant reductions in review timelines. Prolifics enable similar capabilities through integrated data and AI ecosystems that support faster, audit-ready submissions.<\/li>\n\n\n\n<li><strong>Optimized Clinical Trial Screening<\/strong><br>Machine learning models are reducing screen-failure rates and lowering trial costs by identifying the right patient cohorts earlier. At Prolifics, we help organizations design data pipelines and AI models that make clinical trials more predictive and cost-efficient.<\/li>\n\n\n\n<li><strong>Dynamic HCP Engagement<\/strong><br>\u00a0Agentic commercial platforms are transforming how pharma companies interact with healthcare providers by enabling real-time, personalized engagement. Prolifics support this shift by integrating AI with CRM and digital experience platforms to create context-aware interactions.<\/li>\n\n\n\n<li><strong>Advanced Pharmacovigilance<\/strong><br>\u00a0AI-powered agents are analyzing real-world data, including electronic health records, to detect safety signals earlier and more accurately. Prolifics helps implement these solutions with strong governance and compliance frameworks to ensure patient safety and regulatory alignment.<\/li>\n<\/ul>\n\n\n\n<p>At Prolifics, our role is to connect these use cases into a unified, scalable strategy, helping pharmaceutical organizations move from isolated innovation to sustained business impact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Business Impact: Speed, Cost, and Innovation<\/h2>\n\n\n\n<p>Pharma organizations are under constant pressure to bring therapies to market faster while managing rising costs and increasing scientific complexity. Balancing speed, efficiency, and innovation is critical to staying competitive and delivering better patient outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"564\" data-src=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration-1024x564.jpg\" alt=\"Agentic AI for pharma improving speed to market cost efficiency and innovation capacity through pharma AI automation and advanced workflow orchestration\" class=\"wp-image-42402 lazyload\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/564;aspect-ratio:1.815625432885441;width:654px;height:auto\" title=\"\" data-srcset=\"https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration-1024x564.jpg 1024w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration-300x165.jpg 300w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration-768x423.jpg 768w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration-1536x846.jpg 1536w, https:\/\/prolifics.com\/usa\/wp-content\/uploads\/2026\/04\/Agentic-AI-for-pharma-improving-speed-to-market-cost-efficiency-and-innovation-capacity-through-pharma-AI-automation-and-advanced-workflow-orchestration.jpg 1690w\" data-sizes=\"auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" data-original-sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p>The compounding effect of these three dimensions is what makes agentic AI strategically decisive rather than merely operationally useful. A pharma organization that achieves faster regulatory submissions, lower per program costs, and higher scientific output simultaneously does not just improve margins, it can sustain a broader pipeline, take on more indications, and address therapeutic areas that would previously have been considered economically unviable.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p>Agentic AI is no longer a future bet; it is a present-day differentiator. Pharma organizations that move now are already seeing faster timelines, lower costs, and stronger scientific outcomes. The path forward is clear, build the right data foundation, integrate systems, and deploy with measurable business value in mind.<\/p>\n\n\n\n<p>For leaders focused on advancing patient outcomes and driving meaningful impact at scale, agentic AI is becoming essential. Prolifics is ready to partner across this journey, helping turn strategy into real, measurable results.<\/p>\n\n\n<!-- wp:themify-builder\/canvas \/-->","protected":false},"excerpt":{"rendered":"<p>Agentic AI for pharma is at a turning point. As pressure builds to bring therapies to market, manage rising costs, and navigate increasing complexity, traditional ways of working are no [&hellip;]<\/p>\n","protected":false},"author":68,"featured_media":42392,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[49],"tags":[],"class_list":["post-42390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","has-post-title","has-post-date","has-post-category","has-post-tag","has-post-comment","has-post-author",""],"acf":[],"builder_content":"","_links":{"self":[{"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/posts\/42390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/users\/68"}],"replies":[{"embeddable":true,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/comments?post=42390"}],"version-history":[{"count":23,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/posts\/42390\/revisions"}],"predecessor-version":[{"id":42420,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/posts\/42390\/revisions\/42420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/media\/42392"}],"wp:attachment":[{"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/media?parent=42390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/categories?post=42390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prolifics.com\/usa\/wp-json\/wp\/v2\/tags?post=42390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}